Maravai LifeSciences will release Q2 2025 results on August 11, followed by a conference call.
Quiver AI Summary
Maravai LifeSciences, Inc. plans to release its second quarter 2025 financial and operating results on August 11, 2025, after the market closes. The company will host a conference call and webcast that same day at 2:00 p.m. PT/5:00 p.m. ET, with participation available via telephone or online. Maravai is a prominent life sciences firm supplying essential products for drug therapy, diagnostics, and vaccine development, and it serves major biopharmaceutical and research entities globally.
Potential Positives
- Maravai LifeSciences is set to release its financial and operating results for Q2 2025, indicating transparency and commitment to shareholder communication.
- The upcoming conference call and webcast provide an opportunity for stakeholders to engage directly with the company's leadership, enhancing investor relations.
- Maravai is positioned as a leading provider in critical life science markets such as drug therapies and diagnostics, suggesting strong demand for its products and services.
Potential Negatives
- The press release provides no financial results or business updates, leaving investors without important information to assess the company's current position or performance.
- The timing of the financial announcement could indicate a delay or issues with Q2 performance, raising concerns among investors about potential underlying problems.
- Absence of any mention of significant developments or innovations may suggest stagnation, which could be viewed negatively in a competitive market.
FAQ
When will Maravai announce its Q2 2025 results?
Maravai plans to announce its second quarter 2025 financial results on August 11, 2025, after market close.
How can I join the Maravai conference call?
To join the conference call, dial (800) 267-6316 or (203) 518-9783 and reference Conference ID MARAVAI.
What time is the Maravai conference call scheduled?
The conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET on August 11, 2025.
Where can I find the webcast of the Maravai call?
The webcast will be available on the "Investors" section of the Maravai website at https://investors.maravai.com.
What does Maravai LifeSciences do?
Maravai provides life science reagents and services for drug therapies, diagnostics, and vaccine development, supporting human disease research.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MRVI Insider Trading Activity
$MRVI insiders have traded $MRVI stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $MRVI stock by insiders over the last 6 months:
- KURT ORESHACK (General Counsel) sold 25,000 shares for an estimated $125,750
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MRVI Hedge Fund Activity
We have seen 100 institutional investors add shares of $MRVI stock to their portfolio, and 97 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALYESKA INVESTMENT GROUP, L.P. removed 5,329,420 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $11,778,018
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 4,416,389 shares (-94.7%) from their portfolio in Q1 2025, for an estimated $9,760,219
- MIRABELLA FINANCIAL SERVICES LLP added 3,739,951 shares (+inf%) to their portfolio in Q1 2025, for an estimated $8,265,291
- JPMORGAN CHASE & CO removed 3,572,469 shares (-84.0%) from their portfolio in Q1 2025, for an estimated $7,895,156
- JENNISON ASSOCIATES LLC removed 2,990,414 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $6,608,814
- PHILOSOPHY CAPITAL MANAGEMENT LLC added 2,593,268 shares (+inf%) to their portfolio in Q1 2025, for an estimated $5,731,122
- MARSHALL WACE, LLP removed 2,384,485 shares (-85.8%) from their portfolio in Q1 2025, for an estimated $5,269,711
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MRVI Analyst Ratings
Wall Street analysts have issued reports on $MRVI in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Craig-Hallum issued a "Buy" rating on 05/13/2025
- B of A Securities issued a "Buy" rating on 03/03/2025
To track analyst ratings and price targets for $MRVI, check out Quiver Quantitative's $MRVI forecast page.
$MRVI Price Targets
Multiple analysts have issued price targets for $MRVI recently. We have seen 5 analysts offer price targets for $MRVI in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Christian Schwab from Craig-Hallum set a target price of $10.0 on 05/13/2025
- Catherine Schulte from Baird set a target price of $2.0 on 05/13/2025
- Tejas Savant from Morgan Stanley set a target price of $5.0 on 03/25/2025
- Dan Brennan from UBS set a target price of $2.5 on 03/21/2025
- Michael Ryskin from B of A Securities set a target price of $8.0 on 03/03/2025
Full Release
SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2025 financial and operating results after the market close on Monday, August 11, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
To participate in the conference call by telephone, dial (800) 267-6316 or (203) 518-9783 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com .
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
